TVARDI THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
TVARDI THERAPEUTICS, INC. (TVRD) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$6.46 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-14
- TVARDI THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$6.46M.
- TVARDI THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$6.80M.
- TVARDI THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$7.28M.
- TVARDI THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$5.53M.
- TVARDI THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$25.37M.
- TVARDI THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$29.40M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$6.46M 10-Q · filed 2026-08-14 | -$13.26M 10-Q · filed 2026-08-14 | -$20.54M derived: sum of 3 quarters · filed 2026-08-14 | -$26.06M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | -$6.80M 10-Q · filed 2026-05-08 | -$14.08M derived: sum of 2 quarters · filed 2026-05-08 | -$19.61M derived: sum of 3 quarters · filed 2026-05-08 | -$28.10M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | -$7.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$12.80M derived: sum of 2 quarters · filed 2026-03-31 | -$21.29M derived: sum of 3 quarters · filed 2026-08-14 | -$25.37M 10-K · filed 2026-03-31 | |
| 2025-09-30 | -$5.53M 10-Q · filed 2025-11-13 | -$14.02M derived: sum of 2 quarters · filed 2026-08-14 | -$18.10M 10-Q · filed 2025-11-13 | -$36.30M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | -$8.49M 10-Q · filed 2026-08-14 | -$12.57M 10-Q · filed 2026-08-14 | -$30.78M derived: sum of 3 quarters · filed 2026-08-14 | -$36.29M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | -$9.58M 10-Q · filed 2026-05-08 | -$22.29M derived: sum of 2 quarters · filed 2026-05-08 | -$27.80M derived: sum of 3 quarters · filed 2026-05-08 | -$34.77M derived: sum of 4 quarters · filed 2026-05-08 | |
| 2024-12-31 | -$12.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$18.22M derived: sum of 2 quarters · filed 2026-03-31 | -$25.20M derived: sum of 3 quarters · filed 2026-03-31 | -$29.40M 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$5.51M 10-Q · filed 2025-11-13 | -$12.49M derived: sum of 2 quarters · filed 2025-11-13 | -$16.69M 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | -$6.97M 10-Q · filed 2025-08-14 | -$11.18M 10-Q · filed 2025-08-14 | |||
| 2014-06-30 | -$3.65M 10-Q · filed 2014-08-07 | -$7.03M 10-Q · filed 2014-08-07 | |||
| 2013-12-31 | -$2.09M 10-K · filed 2015-03-27 | -$6.67M derived: sum of 2 quarters · filed 2015-03-27 | -$1.24M derived: sum of 3 quarters · filed 2015-03-27 | -$2.99M derived: sum of 4 quarters · filed 2015-03-27 | |
| 2013-09-30 | -$4.58M 10-K · filed 2015-03-27 | $849.00K derived: sum of 2 quarters · filed 2015-03-27 | -$899.00K derived: sum of 3 quarters · filed 2015-03-27 | ||
| 2013-06-30 | $5.42M 10-K · filed 2015-03-27 | $5.34M 10-Q · filed 2014-08-07 | $3.60M 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | -$1.75M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |